Other Information.
−Removed: During the quarter ended September 30, 2025, none of our directors or officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted , modified or terminated a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement” (as each term is defined in Item 408 of Regulation S-K).
+Added: The following table describes for the quarterly period covered by this report each trading arrangement for the purchase or sale of the Company’s securities adopted , modified or terminated by our directors and officers that is either (1) a contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c), or a “Rule 10b5-1 trading arrangement,” or (2) a “non-Rule 10b5-1 trading arrangement” (as defined in Item 408(c) of Regulation S-K):
+Added: Name (Title) Action Taken (Date of Action) Type of Trading Arrangement Nature of Trading Arrangement Duration of Trading Arrangement Aggregate Number of Securities
+Added: ( Co-Founder, Chief Executive Officer, and Chairman of the Board of Directors )
+Added: ( March 10, 2026 )
+Added: Rule 10b5-1 trading arrangement Sale July 10, 2027
+Added: (i) up to 892,123 ADSs to be sold by Mr.
+Added: (ii) up to such net number of ADSs to be received upon vesting of unvested RSUs in 2026 after sell-to-cover for withholding tax, to be sold by Mr.
+Added: (iii) up to 60,010 ADSs to be sold by the Pan-Oyler Foundation.
See the Exhibit Index below for a list of the exhibits filed as part of, or incorporated by reference into, this Quarterly Report, which Exhibit Index is incorporated herein by reference.
1 unchanged sentence
Exhibit Description Filed/Furnished Herewith Incorporated by Reference Herein from Form or Schedule Filing Date SEC File / Reg.
−Removed: 10.1# Royalty Purchase Agreement, dated August 25, 2025, by and between the Registrant, BeOne Medicines I GmbH, and Royalty Pharma Investments 2023 ICAV.
−Removed: 10.2# Waiver under Collaboration Agreement , dated August 11, 2025 , by and between the Registrant, BeOne Medicines I G mb H , and Amgen Inc.
+Added: 10.1 Independent Non-Executive Director Compensation Policy, as amended
+Added: 10.2 Form of Global Restricted Share Unit Award Agreement for Non-Employee Directors under the Fourth Amended and Restated 2016 Share Option and Incentive Plan
31.1 Certification of Principal Executive Officer Required Under Rule 13a‑14(a) and 15d‑14(a) of the Securities Exchange Act of 1934, as amended
9 unchanged sentences
* Furnished herewith.
−Removed: # Certain portions of the exhibit have been omitted by means of redacting a portion of the text and replacing it with “[…***…]”, because they are both (i) not material and (ii) the type of information that the Registrant treats as private or confidential.
+Added: # Indicates a management contract or any compensatory plan, contract or arrangement.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
BEONE MEDICINES LTD.
−Removed: November 6, 2025 By:
+Added: May 6, 2026 By:
Chief Executive Officer and Chairman
(Principal Executive Officer)
−Removed: November 6, 2025 By:
+Added: May 6, 2026 By:
/s/ Aaron Rosenberg
3 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.